PATENT CLAIM ANALYSIS

Application Number: 15760170
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "450000"]

Abstract:
Lipid nanoparticles and methods of making and using the same, including pharmaceutical compositions and kits, and the targeted delivery of drugs in various treatment methods. The nanoparticle formulation includes phospholipids, triglycerides, cholesterol, cholesteryl ester, apolipoprotein E3 (ApoE3), and a lipophilic therapeutic agent.

Claim (Index 33):
A composition, comprising:\n lipid nanoparticles in lipoprotein free serum, the lipid nanoparticles being coated with human recombinant E3 lipoprotein (ApoE3), and loaded with Docetaxel without any Polysorbate 80,\n wherein the composition has a lower IC50 inhibitory concentration and a higher selectivity index than Docetaxel in its regular formulation with Polysorbate 80.

Metadata:
- Claim Count in Document: 66.0
- Percentile: 90.0
- Lexical Diversity: 1.35897
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10724833', '11648808', '11802197', '11513756', '11802727']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7183007020867167
- 35 USC 102 Novelty (BERT): 0.5199127144011635
- Combined Prediction Score: 0.6984619033181615
- Mean Citation Score: 279.559728
- Max Citation Score: 291.0936
- Similarity Product: 192.2082066272736

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test